|
Match
|
Document |
Document Title |
|
|
US20110087152 |
FLUIDIC TISSUE AUGMENTATION COMPOSITIONS AND METHODS
Compositions and method for augmenting tissue after delivery to localized area. The compositions include a hydrogel and a dermal filler. The hydrogel can polymerize and/or crosslink upon a first... |
|
|
US20160175436 |
COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES
In alternative embodiments, this invention provides compositions and methods for treating cancer or any condition caused by dysfunctional cells, side effects from treatments for cancer or any... |
|
|
US20050171031 |
Method and composition for the treatment of cancer
We have discovered that the administration of a G1 and/or S phase drug such as β-lapachone in combination with a G2/M drug such as a taxane derivative such as paclitaxel resulted in a unexpected... |
|
|
US20100330159 |
System for transporting active substances in a biological system
A stabilizer-free system for transporting active substances in a biological system of one or more active substances and magnetic particles, which is characterized in that the particles are... |
|
|
US20090053234 |
Methods of Preventing or Treating Inflammatory or Autoimmune Disorders by Administering Integrin ALPHAVBETA3 Antogonists in Combination with other Prophylactic or Therapeutic Agents
The present invention provides to methods of preventing, treating or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder utilizing combinatorial therapy. In... |
|
|
US20130225690 |
VITAMIN K FOR PREVENTION AND TREATMENT OF SKIN RASH SECONDARY TO ANTI-EGFR THERAPY
The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a... |
|
|
US20100239666 |
Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding
The invention relates to a process for producing mouldings by injection moulding the steps in the process being a) melting and mixing of a (meth)acrylate copolymer composed of from 85 to 98% by... |
|
|
US20070135376 |
METHOD TO REDUCE OXIDATIVE DAMAGE AND IMPROVE MITOCHONDRIAL EFFICIENCY
Methods for the reduction of mitochondrial oxidative damage and improved mitochondrial efficiency in an animal by administration of medium chain triglycerides or prodrug of medium chain... |
|
|
US20070123448 |
Novel chemical entities affecting neuroblastoma tumor-initiating cells
Disclosed are neuroblastoma tumor-initiating cell inhibiting compositions comprising chemical entities capable of affecting neuroblastoma tumor-initiating cells. Pharmaceutical preparations that... |
|
|
US20090036387 |
NOVEL CHEMICAL ENTITIES AFFECTING NEUROBLASTOMA TUMOR-INITIATING CELLS
Disclosed are neuroblastoma tumor-initiating cell inhibiting compositions comprising chemical entities capable of affecting neuroblastoma tumor-initiating cells. Pharmaceutical preparations that... |
|
|
US20100204244 |
AGENTS FOR TREATMENT OF DIABETIC RETINOPATHY AND DRUSEN FORMATION IN MACULAR DEGENERATION
Agents that stimulate nuclear translocation of Nrf2 protein and the subsequent increases in gene products that detoxify and eliminate cytotoxic metabolites are provided in a method for treating... |
|
|
US20110305758 |
ORALLY DISINTEGRATING TABLET HAVING INNER CORE
The present invention provides an orally disintegrating tablet with improved photostability of a medicament unstable to light. The orally disintegrating tablet has an inner core and an outer layer... |
|
|
US20110288161 |
METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS
Certain embodiments in the present invention provide for methods for therapy of lung diseases and other conditions such as infection are provided. In certain embodiments, the methods comprise one... |
|
|
US20090239952 |
VITAMIN K FOR PREVENTION AND TREATMENT OF SKIN RASH SECONDARY TO ANTI-EGFR THERAPY
The invention provides methods and compositions tor treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (BGKR) therapy, where the method comprises applying a... |
|
|
US20080221029 |
METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS
Certain embodiments in the present invention provide for methods for therapy of lung diseases and other conditions such as infection are provided. In certain embodiments, the methods comprise one... |
|
|
US20070026072 |
Benzoquinones of enhanced bioavailability
Benzoquinone compositions of enhanced solubility and bioavailability are described that contain at least one benzoquinone with at least one solubility-enhancing polymer. In one embodiment, the... |
|
|
US20140336268 |
FORMULATIONS OF VITAMIN K ANALOGS FOR TOPICAL USE
The present invention provides topical formulations containing a vitamin K analog, e.g., menadione, that deliver a uniform, therapeutically effective concentration of the vitamin K analog to the... |
|
|
US20120135050 |
EXTENDED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF
Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition... |
|
|
US20070122490 |
Wound healing compound
This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprise a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound... |
|
|
US20140186328 |
NEUROPROTECTIVE POLYPHENOL ANALOGS
The present invention provides neuroprotective polyphenol compounds, which can be synthetic analogs of fisetin, baicalein or chlorogenic acid, that maintain neuroprotective, anti-inflammatory,... |
|
|
US20120039796 |
Novel method for creating, suspending and stabilizing electronically modified oxygen derivatives, along with creating, suspending and stabilizing electronically modified reaction intermediates, in a bio compatible fluorocarbon suspension, for the purpose of inducing a cascading immune response in mammalian patients
A bio compatible free radical suspension, comprising of oxygen and electronically modified reaction intermediates, where a fluorocarbon is used as an inert medium for stabilization of reaction... |
|
|
US20150272968 |
EXTENDED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF
Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition... |
|
|
US20060275237 |
Skin care compositions containing idebenone
A stable skin care composition, comprising an effective amount of idebenone, at least one additional skin care active, and a dermatologically acceptable carrier. |
|
|
US20120009169 |
SELF-FORMING PHOSPHOLIPIDIC GELS
A phospholipid gel is spontaneously formed when combining a first phospholipid, a second phospholipid, and water, wherein the first phospholipid is a neutral phospholipid and the second... |
|
|
US20100029784 |
NAPHTHOQUINONE COMPOSITIONS WITH ANTI-AGING, ANTI-INFLAMMATORY AND SKIN EVEN-TONING PROPERTIES
The present invention relates to methods and compositions comprising naphthoquinones such as 2,3-dimethylnaphthalene-1,4-dione, for the use of treating, regulating or preventing a skin condition... |
|
|
US20090030086 |
ANTIMICROBIAL AGENTS
A benzoquinone or hydroquinone for use in the topical treatment of a condition which is caused, exacerbated or transmitted by bacterial, in particular staphylococcal or propionibacterial,... |
|
|
US20120244221 |
EXTENDED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF
Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition... |
|
|
US20100048704 |
PHARMACEUTICAL AND NUTRACEUTICAL PRODUCTS COMPRISING VITAMIN K2
A pharmaceutical and nutraceutical product is provided comprising vitamin K2 or a compound within the vitamin K2 class of compounds, optionally and preferably in combination with one or more... |
|
|
US20060275909 |
Nutrition formulations and methods of providing nutrition formulations
Nutritional compositions such as total parenteral nutrition (TPN) compositions and processes of preparing same are disclosed. The advantage of the present invention lies in its ability to tailor... |
|
|
US20060178435 |
Apogossypolone and the uses thereof
The invention relates to the compound apogossypolone and salts and prodrugs thereof. Apogossypolone functions as an inhibitor of Bcl-2 family proteins. The invention also relates to the use of... |
|
|
US20060166948 |
Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries
Vitamin K is effective in counteracting the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin... |
|
|
US20140348810 |
ABSORBABLE IN SITU GEL-FORMING SYSTEM, METHOD OF MAKING AND USE THEREOF
An in situ gel-forming composition is disclosed. The in situ gel-forming composition comprises one or more absorbable polymers, solvents such as N-methyl-2-pyrrolidone, polyethylene glycol or... |
|
|
US20070025950 |
COMPOSITION AND METHOD FOR TREATING CELLULITE
A composition for reducing the appearance of cellulite is provided that comprises guarana extract and vitamin K. In addition, a method of treating cellulite with a topical composition comprising... |
|
|
US20060093651 |
Food materials useful in preventing and ameliorating metabolic bone diseases and preventives/remedies for metabolic bone diseases comprising these materials
This invention relates to drinks and foods having osteogenetic function, each of which comprises as an active ingredient an effective amount of a culture of a propionic acid bacterium and/or a... |
|
|
US20120141554 |
DELAYED RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF
Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition... |
|
|
US20070142462 |
Method of Treating Cancer
Methods for treating cancer are provided including administering a patient needing treatment a therapeutically effective amount of one or more antioxidants selected from the group of catalase,... |
|
|
US20130196012 |
EXTENDED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF
Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition... |
|
|
US20060275504 |
Methods and compositions for augmenting cancer chemotherapeutic agents
This invention provides methods and pharmaceutical compositions/therapy combination product for cancer treatment and/or augmenting the effectiveness of cancer chemotherapeutic agents by use of a... |
|
|
US20070099871 |
Bioreductively-activated prodrugs
The present invention relates to a compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein: Ar is a substituted aryl or heteroaryl group bearing at least one nitro or azido... |
|
|
US20150164824 |
METHODS AND COMPOSITIONS USEFUL FOR IMPROVING BONE AND JOINT HEALTH
Compositions for improving bone health, joint health, or both in an individual in need thereof are provided, along with methods of using the compositions. Generally, the compositions include a... |
|
|
US20090053209 |
Blockade of Pin1 Prevents Cytokine Production by Activated Immune Cells
The invention provides pharmaceutical compositions and methods of treating immunological disorders. The invention also provides pharmaceutical compositions and methods of inducing eosinophil... |
|
|
US20050215625 |
Combination therapy for anticoagulation
A combination anticoagulation medicament including vitamin K with warfarin in an oral form is described. Between 50 and 5000 micrograms of vitamin K are combined in a single oral medication with... |
|
|
US20110158983 |
COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES
In alternative embodiments, this invention provides compositions and methods for treating cancer or any condition caused by dysfunctional cells, side effects from treatments for cancer or any... |
|
|
US20070032557 |
Method for administering levosimendan
The invention relates to intermittent administration of an inotropic agent (such as, but not limited to a levosimendan compound) or a pharmaceutically acceptable salt thereof in the treatment of... |
|
|
US20150250726 |
Nanoscale Bound Bilayers, Methods of Use and Production
Methods for rapidly obtaining a nanoscale apolipoprotein bound phospholipid bilayer (NABB) associated with at least one membrane protein are provided. Also disclosed are methods for rapidly... |
|
|
US20100297251 |
ENCAPSULATED PARTICLES FOR ENTERIC RELEASE
The present invention provides a system for delivery of an enteric coated active agent generally resistant to disintegration in an neutral environment having one or more active agents encapsulated... |
|
|
US20140343165 |
PLANT PROTECTION AGENT
A method for combating bacterial infections in plants including the step of applying a plant protection agent onto the blossoms and/or leaves of the plants. The plant protection agent includes a... |
|
|
US20120100077 |
MIXTURE OF AMPHIPATHIC MOLECULES AND METHOD FOR MODIFYING CELL MEMBRANES BY MEANS OF FUSION
Disclosed is a mixture of amphipathic molecules and a method for modifying cells in vivo by way of membrane fusion with these molecules. |
|
|
US20050123603 |
Natural menaquinone 7 compositions
The present invention relates to the field of human nutrition, and in particular to pharmaceutical compositions and nutritional supplements comprising an effective daily dose of menaquinone 7. In... |
|
|
US20130150429 |
P27KIP1 AS A MOLECULAR MARKER FOR SUITABILITY AND EFFICACY OF TREATMENT WITH HSP27 INHIBITORS
Cells expressingHsp27 exhibit reduced levels of p27kip1. Accordingly, a method for treatment of cancer using hsp27 inhibition that includes a preliminary test to ascertain the status of the... |